Viridian Therapeutics, Inc.\DE financial data

Symbol
VRDN on Nasdaq
Industry
Services-Medical Laboratories
Location
221 Crescent Street, Suite 103 A, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
MIRAGEN THERAPEUTICS, INC. (to 1/15/2021), SIGNAL GENETICS, INC. (to 2/10/2017), SIGNAL GENETICS LLC (to 7/9/2014)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.88K % +45.6%
Debt-to-equity 9.6 % -17.7%
Return On Equity -45.5 % +29.4%
Return On Assets -41.5 % +28.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 79.2M shares +50.6%
Common Stock, Shares, Outstanding 79.2M shares +81.2%
Entity Public Float 1.02B USD +210%
Common Stock, Value, Issued 792K USD +81.2%
Weighted Average Number of Shares Outstanding, Basic 66.4M shares +52.1%
Weighted Average Number of Shares Outstanding, Diluted 66.4M shares +52.1%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 78.5M USD +9.23%
Operating Income (Loss) -283M USD -22%
Nonoperating Income (Expense) 26M USD +68.8%
Net Income (Loss) Attributable to Parent -257M USD -18.7%
Earnings Per Share, Basic -4.3 USD/shares +16%
Earnings Per Share, Diluted -4.3 USD/shares +16%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash, Cash Equivalents, and Short-term Investments 753M USD +141%
Assets, Current 767M USD +137%
Property, Plant and Equipment, Net 1.29M USD -28.3%
Operating Lease, Right-of-Use Asset 2.4M USD +29.4%
Other Assets, Noncurrent 853K USD -32.5%
Assets 772M USD +135%
Accounts Payable, Current 6.34M USD +69.7%
Employee-related Liabilities, Current 10M USD +30.9%
Accrued Liabilities, Current 34.7M USD +80.7%
Contract with Customer, Liability, Current 288K USD 0%
Liabilities, Current 41.4M USD +77.9%
Contract with Customer, Liability, Noncurrent 356K USD -44.8%
Operating Lease, Liability, Noncurrent 2.2M USD +83.3%
Other Liabilities, Noncurrent 2.16M USD +67.6%
Liabilities 64.4M USD +42.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 932K USD
Retained Earnings (Accumulated Deficit) -916M USD -39%
Stockholders' Equity Attributable to Parent 707M USD +149%
Liabilities and Equity 772M USD +135%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -45.2M USD +27%
Net Cash Provided by (Used in) Financing Activities 177M USD +2058%
Net Cash Provided by (Used in) Investing Activities -143M USD -976%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 79.2M shares +81.2%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.2M USD +83.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 200M USD +79.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 452K USD +304%
Deferred Tax Assets, Valuation Allowance 156M USD +79.8%
Deferred Tax Assets, Gross 156M USD +79.7%
Operating Lease, Liability 2.75M USD +35.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -256M USD -18.7%
Lessee, Operating Lease, Liability, to be Paid 3.35M USD +46.2%
Property, Plant and Equipment, Gross 2.72M USD -18.3%
Operating Lease, Liability, Current 589K USD -28.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 748K USD +61.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 723K USD -24.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 603K USD +127%
Lessee, Operating Lease, Liability, to be Paid, Year Three 613K USD +29.3%
Deferred Tax Assets, Operating Loss Carryforwards 67.8M USD +47.3%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 627K USD +294%
Additional Paid in Capital 1.43B USD +77.5%
Depreciation, Depletion and Amortization 145K USD +38.1%
Deferred Tax Assets, Net of Valuation Allowance 0 USD -100%
Share-based Payment Arrangement, Expense 59.2M USD +27.6%
Interest Expense 700K USD 0%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%